FDA Type C Meeting Resets ATYR Efzofitimod with Clearer Regulatory Alignment

Research evidence excerpt

FDA Type C Meeting Resets ATYR Efzofitimod with Clearer Regulatory Alignment

USA | Biotechnology

aTyr Pharma EquityMayResearch12, 2026

FLASH NOTEFDA Type C Meeting Resets ATYR Efzofitimod

RATING BUYwith Clearer Regulatory Alignment

PRICE $0.95^

The FDA Type C meeting provides long-needed regulatory clarity for

efzofitimod, resetting the pulmonary sarcoidosis program around a new, FDA- PRICE TARGET | % TO PT $3.00 | +216%

aligned Ph3 trial focused on FVC and a more severe, restrictive pt population 52W HIGH-LOW $7.29 - $0.64

(FVC ≤80%). As regulatory uncertainty eases, success hinges on confirming a FLOAT (%) | ADV MM (USD) 97.6% | 0.99

subgroup signal in a larger, longer global study, shifting focus to a population MARKET CAP $93.1M

where efzofitimod has already shown promise. TICKER ATYR ^Prior trading day's closing price unless otherwise

noted.

Bottom line. ATYR has secured FDA alignment on a new Ph3 plan (C006) for efzofitimod in

pulmonary sarcoidosis following a Type C meeting (minutes received 05/11/26). The FDA endorsed

FVC (change from baseline) as the 1EP and KSQ-Lung as a key 2EP (QoL). This regulatory clarity

may resuscitate efzofitimod by focusing on clinically meaningful EPs through a new, larger Ph3,

and extending the timeline (likely by 2+ yrs) for potential approval. We view the strategy pivot as

constructive (aligning w/FDA’s preferences and prior data signals), despite execution and data risks

remaining.

Ph3 study design. Population moderate-to-severe sarcoidosis pts w/“restrictive” lung disease

(baseline FVC ≤80% predicted). EFZO-FIT post-hoc analysis showed that subgroup (n=44) had a

~124mL greater FVC improvement on efzofitimod vs pbo. N = ~372 pts randomized 1:1 to efzo

5.0 mg/kg IV or pbo Q3W for 54W (17 doses).